Incretin based therapy and pancreatic cancer: Realising the reality

Pancreatic cancer and incretin therapy

Varun Suryadevara, Ayan Roy, Jayaprakash Sahoo, Sadishkumar Kamalanathan, Dukhabandhu Naik, Pazhanivel Mohan, Raja Kalayarasen
Abstract
Incretin-based therapies like glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help maintain the glycaemic control in patients with type 2 diabetes mellitus with little risk of hypoglycaemia and additional systemic benefits. These medications are associated with low-grade chronic pancreatitis in animal models inconsistently. The incidence of acute pancreatitis was also reported in some human studies. This inflammation provides fertile ground for developing pancreatic carcinoma (PC). Although the data from clinical trials and population-based studies have established safety regarding PC, the pathophysiological possibility that low-grade chronic pancreatitis leads to PC remains. We review the existing literature and describe the relationship between incretin-based therapies and PC

Key Words: Diabetes mellitus; Dipeptidyl peptidase-4 inhibitor; Glucagon-like peptide-1 receptor agonists; Incretins; Pancreatitis; Pancreatic Cancer


Core Tip: Incretin-based therapies are being increasingly used to treat patients with type 2 diabetes mellitus. The early literature regarding pancreatic safety of incretin-based therapies was discordant. However, the follow-up data of various randomised trials have consistently shown that these medications are safe.

INTRODUCTION

Introduction:
Incretin-based therapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4Is) are being increasingly used to treat patients with type 2 diabetes mellitus (T2DM). GLP-1 RAs mimic the action of
endogenous glucagon-like peptide-1 (GLP-1), whereas DPP-4Is prevent the degradation of GLP-1. These medications can control blood glucose levels without an increased risk of hypoglycemic episodes or weight gain. The initial clinical trials for GLP-1 RA and DPP-4I were conducted in 2003 and 2004, respectively. The United States Food and Drug Administration (FDA) issued an alert regarding the potential risk of acute pancreatitis in 2007. DPP-4Is have been widely used owing to the oral administration and low risk of hypoglycemia. However, the use of GLP-1 RA was limited until 2015. But the data from cardiovascular outcome trials (CVOTs) of GLP-1 RAs changed the scenario. The significant reduction in cardiovascular deaths with GLP-1 RAs such as liraglutide and semaglutide tilted the benefit-risk relationship. These therapies have become the next treatment choice after metformin in patients with or at high risk of atherosclerotic vascular disease (ASCVD). Newer generation incretin-based therapies [coagonists of GLP1 with gastric inhibitory peptide (GIP) or glucagon] are in the pipeline. They are presumed to have higher efficacy than GLP-1 RAs and DPP-4Is. Various incretin-based medications categorised according to their mechanism of action are shown in table 1.

Incretin-based therapies are speculated to induce overstimulation of the GLP-1 receptor, leading to pancreatitis and pancreatic carcinoma (PC). However, the risk of both PC and pancreatitis is increased in diabetes mellitus (DM) compared to non-diabetic counterparts. For PC, inflammation is relevant both as a risk factor and an effect of cancer. Patients with chronic pancreatitis carry a higher risk of developing PC. The initial postmarketing surveillance studies for incretin-based therapies revealed an increase in pancreatic adverse events. Further observational studies of pancreatic adverse events showed conflicting results. Post hoc analyses of pertinent randomized controlled trials (RCTs) failed to distinguish pancreatic adverse events between controls and patients on incretin-based therapies. However, the theoretical plausibility of PC in patients receiving incretin-based therapies still remains valid. It is worth reviewing the status of the incretin-based therapies now as an increasing number of therapies
based on incretin are becoming available. The treating clinician must be aware of the benefit-risk ratio when prescribing incretin-based therapy.

**Search strategy:**

Two authors (VS, AR) conducted the initial PubMed search for relevant articles. The references of these articles were searched for additional relevant studies. The keywords used in the search were: ‘incretin’; ‘pancreatic cancer’; glucagon-like peptide-1 receptor agonist’; ‘dipeptidyl peptidase-4 inhibitor’; incretin and pancreatic cancer; ‘GLP1-RA and pancreatic cancer’; ‘DPP-4I and pancreatic cancer’. Only English language publications were included. SK, DN, and JS selected the appropriate articles to be included.

**Pathophysiology:**

The critical pathophysiologic mechanisms for developing PC in patients using incretin-based therapies are chronic low-grade inflammation and proliferative changes. A flowchart summarising the pathophysiology of pancreatic cancer is shown as figure 1.

**Role of inflammation**

Even without any therapy, both PC and pancreatitis incidence is increased in T2DM[8,9]. Long term treatment of T2DM patients with DPP-4is/GLP-1 RAs may exacerbate the pre-existing chronic inflammation. Any additional mutations in the background of inflammation can tilt the balance toward the progression of neoplasia. Various researchers conducted animal studies to substantiate this hypothesis using rodents with mutant Kirsten rat sarcoma virus gene (K-RAS), leading to constitutive activation. The K-RAS gene is mutated in > 90% of human PC cases[10]. KC mice model has a single activating mutation (G12D) in the K-RAS gene. Prenatal expression of mutant K-RAS in all exocrine lineages of KC mice resulted in histological changes suggestive of pancreatitis, implying a cooperative relationship between K-RAS activation and inflammation. Treatment of KC mice with the pancreatitis-inducing agent caerulein (a cholecystokinin analog) dramatically accelerates the progression to pancreatic ductal adenocarcinoma (PDAC) within a few weeks[11]. Further animal
experiments have shown that K-RAS mutation alone cannot reach the expected theoretical levels of activity required for the progression of carcinogenesis. Nevertheless, agents which cause inflammation can hyperstimulate K-RAS by modulating its activity above the putative threshold necessary for carcinogenesis. The constitutive activation NF-kB pathway in addition to K-RAS in acinar cells significantly accelerates carcinogenesis, whereas cyclooxygenase inhibition is associated with a reduced risk of PDAC. These findings highlight the importance of inflammation in the progression of PDAC[12].

Incretin-based medications induced pancreatitis in animal experiments[13-15]. Exenatide treatment accelerated pancreatitis in the KC mice[14]. However, most PDAC cases develop without clinically apparent acute or chronic pancreatitis[16]. This observation can be explained by low-grade subclinical inflammation being sufficient to promote carcinogenesis in the presence of additional drivers of carcinogenesis. On the other hand, it can also be a consequence of the earliest events in carcinogenesis.

**Role of proliferative changes**

In addition to low-grade asymptomatic chronic pancreatitis, incretin-based medications induce proliferative changes in the islets. Premalignant changes that precede the onset of PDAC are known as pancreatic intraepithelial neoplasia (PanIN) lesions. They herald the start of PDAC. PanINs can be found in up to 50% of the middle-aged population. However, only a few progress to PDAC[17]. As progression of PanINs to PDAC occurs via the accumulation of additional somatic mutations, any factor that increases cellular replication in PanINs is likely to increase the likelihood of PDAC. Both PanINs and PDAC express the human GLP-1 receptor. Acinar and duct cells proliferate in response to incretin-based medications in the normal pancreas and cause an increase in pancreatic weight[18]. Any factor that increases cellular replication in PanINs may further increase the accumulation of somatic mutations. In the setting of chronic pancreatitis, as shown in animal models treated with incretin-based therapies, this proliferation may be sufficient to initiate carcinogenesis event sequences. Treatment
with exenatide in KC mice resulted in the formation and growth of dysplastic PanIN lesions in addition to pancreatitis\textsuperscript{14}.

**Histological changes following incretin-based therapies**

The controversy of pancreatic adverse events due to incretin-based therapies was amplified by a publication by Butler et al in 2013\textsuperscript{19}. The authors examined age-matched organ donor samples obtained from the Network for Pancreatic Organ Donation (nPOD). They included a total of 34 subjects with T2DM treated with incretin-based therapies \((n = 8)\) or non-incretin-based therapies \((n = 12)\) and nondiabetic control subjects \((n = 14)\). The incretin group had increase in pancreatic mass by 40% with increased exocrine cell proliferation and dysplasia. The authors also noticed alpha and beta-cell hyperplasia along with glucagon-expressing microadenomas in incretin-treated subjects. Islet cell costaining for insulin and glucagon was higher in DM subjects than non-DM control subjects and increased further with incretin therapy. The authors concluded that incretin therapy in humans results in the expansion of both exocrine and endocrine pancreatic compartments and that there is a potential for evolution into neuroendocrine tumors. However, this study was met with sharp criticism owing to methodological flaws. Harja et al\textsuperscript{20}, in a more detailed analysis of the nPOD database, found that the baseline characteristics were not comparable between the incretin group and the other two groups. Pancreatic weight data were missing for half of the subjects. The increase in PanINs can explain the nearly 20-year age difference between the incretin group and the other two groups. Bonner-Weier et al\textsuperscript{21}, and Kahn et al\textsuperscript{22} also re-analyzed the data from nPOD and reached similar conclusions.

Despite the flaws in the study methodology, this study caught the attention of the FDA and the European Medicines Agency (EMA). Both agencies reviewed all available animal and human data for incretin-based therapies. Microscopic examinations from animal studies did not reveal pancreatic lesions or pancreatitis. Even at doses greater than human clinical exposure to incretin-based therapies, there were no tumours in rodents for up to 2 years (lifespan of rodents). The FDA studied the effect of exenatide in Zucker diabetic fatty rat, a chemical-induced pancreatitis model, and C57
black 6 (C57BL/6) high-fat diet mouse model. There was no identifiable pancreatic pathology in the pancreatitis mouse model and Zucker diabetic fatty rat model. After three months of exenatide in the C57BL/6 high-fat diet mouse, a minimal-to-moderate worsening of background findings was noted. Based on the available data, they could not draw any conclusions about the risk of pancreatic adverse events in patients using incretin-based therapies[23].

Ueberberg et al[24] conducted a study on cadaveric pancreata, similar to Butler et al[19]. They obtained pancreatic tissue during surgery from 13 diabetic patients (7 in the incretin group and 6 in the non-incretin group), 11 non-diabetic controls, and nine brain-dead organ donors. There were no differences between groups in the alpha cell area, beta and alpha cell replication, acinar and ductal cell replication. Coexpression of insulin and glucagon has not been demonstrated. PanIN lesions were more common in the diabetic group, although the prevalence was low. Considering the small sample size and large interindividual variability, the authors advised caution on coming to any conclusion from such studies.

Chadwick et al[25] attempted to determine the background incidence of spontaneous pancreatic lesions in different rat strains fed a standard or high-fat diet over four months. They found that the pancreatic lesions previously thought to be due to incretins are common baseline findings. These lesions can be seen without any drug treatment. These lesions were independent of diet or glycaemic status. The authors concluded that we need to be cautious when interpreting patients' pancreatic findings on incretin-based therapies. Aston-Mourney et al[26] tried to characterize the amyloidogenic potential of sitagliptin in rodents. Human islet amyloid polypeptide transgenic mice, untreated nontransgenic mice, and those on treatment with sitagliptin, metformin, or the combination were followed up to one year. There was no increase in amyloid formation or ductal proliferation. However, there was an improvement in β-cell secretion, suggesting endocrine protective effects without associated toxicity to the exocrine compartment of the pancreas.

**Effect of incretin-based therapies on cancer cells-**
The effect of incretin-based therapies on PC cells has also been studied in vitro. Lu et al.\(^{27}\) found that liraglutide in combination with metformin has synergistic antitumor effects in vitro. Yan et al.\(^{28}\) examined the effect of exendin-4 on a xenograft tumor model. Exendin-4 suppressed the PC cell proliferation by attenuating the function of pancreatic stellate cells (PSC) and suppressing extracellular matrix deposition. Zhao et al.\(^{29}\) examined the effect of liraglutide on PC cell line (PANC-1) cocultured with and without PSCs and found that liraglutide significantly reduced the migration and invasion of the PANC-1 cells. The authors hypothesized that the effect is probably mediated by calcium and calcium-binding proteins. In another study, Zhao et al.\(^{30}\) examined the effects of liraglutide on the chemosensitivity of PC cells to gemcitabine in PANC-1 and gemcitabine resistant cell lines (PANC-GR). Liraglutide inhibited proliferation and promoted apoptosis of the PANC-GR cells in a dose-dependent manner. It also increased GLP-1 receptor and protein kinase-A expression in the PANC-GR cells. In rodent studies, liraglutide treatment was observed to increase the chemosensitivity of PC cells to gemcitabine.

**DPP4 and cancer**

DPP-4 cleaves many other polypeptides, such as chemokines, neuropeptides in addition to GLP-1. DPP-4, also known as cluster differentiation marker 26 (CD26), plays a vital role in inflammation by modulating the inactivation of cytokines and chemokines. DPP-4 is expressed in various malignancies. The overexpression of DPP-4 exerts an antitumour effect predominantly through immunomodulation\(^{31}\). DPP-4 inhibition has been shown to improve antitumor immune response by preserving the function of a chemokine C-X-C motif ligand (CXCL10) and through interleukin 33 (IL-33) mediated tumour control\(^{32,33}\). The effects of DPP-4 on cancer cells appear to be heterogeneous, depending on tumor types, stages, microenvironment, and host condition. In breast cancer and small cell lung cancers, decreased expression of DPP-4 is associated with more aggressiveness of the tumour. However, increased DPP-4 expression levels have been associated with poor prognosis in patients with PC\(^{31}\).
Incretin-based therapies and PC- human studies:

Data from observational studies -

Early case reports of pancreatitis following exenatide and sitagliptin led to the issue of FDA alert in 2007. These reports led to many database analyses to look for the prevalence of pancreas-related adverse events. Elashoff et al.\(^6\) raised concern regarding PDAC by studying the FDA adverse events reporting system (FDA AERS) during 2004-09. This study resulted in widespread coverage in media regarding the risk of PC. Elashoff et al. examined FDA AERS database for adverse events associated with exenatide and sitagliptin in this study. The odds ratio for reported pancreatitis was 6-fold higher for sitagliptin or exenatide users than other therapies. PC was also more frequent (approximately 3-fold) among patients who took sitagliptin or exenatide. However, we must understand that this was a retrospective, record-based study. The likelihood of reporting events is higher with new drugs than with the patients on older drugs. A series of observational studies followed this study and showed discordant results. Most of the observational studies were retrospective and record-based. Both the FDA and the EMA reviewed their clinical safety databases, and the pooled data did not reveal any compelling evidence of an increased risk of pancreatitis or PC.

The latest observational study from Montvida et al.\(^{34}\) used Centricity Electronic Medical Records from the USA. The authors assessed the time to pancreatic events for incretin-based and nonincretin therapies (sulfonylurea, thiazolidinedione, and insulin). This study surprisingly found that the group treated with insulin had higher pancreatitis events with a short time compared to incretin-based therapies. For PC, the time to event rate was not significantly different between the groups. Among the older studies, few studies showed an increased risk of pancreatitis and PC, but most studies could not find any association between pancreatic adverse events and incretin-based therapies. Although the sample size was adequate for these studies, we must keep in mind the unaccounted confounders. The baseline characteristics and the comparator drugs varied among different studies. A summary of these studies is compiled in table 2.
**Data from randomised controlled trials**

Data from RCTs have conventionally been considered superior to data from observational studies. There have been many follow-up studies of the patients recruited for cardiovascular outcome trials (CVOT) of the incretin-based therapies. Among the individual CVOT data, there was a non-significant trend for or against the development of PC for different incretin-based therapies. Many researchers also assessed the PC risk with incretin-based therapies using meta-analyses and systematic reviews. Alves *et al*[^44] evaluated the association of lixisenatide or exenatide with PC in a meta-analysis that included 25 Longitudinal studies in 2012. Neither GLP1- RAs nor DPP-4Is were associated with increased risk for PC.

The first meta-analysis evaluating PC association with all types of incretin-based therapies was published by Chen *et al*[^43] in 2016. This meta-analysis included 24 RCTs enrolling 47904 patients. This meta-analysis also could not identify any increased risk of PC either as monotherapy [risk ratio (RR) = 0.62, 95%CI 0.38-1.01] or combination therapy (RR = 0.92, 95%CI 0.45-1.90). This result was followed by a series of meta-analyses with a similar conclusion. The latest meta-analysis is from Aziz *et al*[^51], which evaluated 11 CVOTs studying 55921 patients. In the individual study data, lixisenatide and semaglutide were associated with nominally reduced RR, whereas liрагlutide was associated with a slightly elevated RR. However, none of these risk ratios were statistically significant. In this meta-analysis, neither GLP-1 RAs nor DPP-4Is were associated with a significant increase or decrease in risk of PC [RR for PC- for GLP-1 RA 0.99 (95%CI 0.9-1.08); DPP-4I 0.92 (95%CI 0.83-1.01)]. The summary of the data from various meta-analyses is compiled in table 3.

**Newer Incretin-based therapies**

Tirzepatide is a dual agonist at GLP-1 and GIP receptors. It was formulated as a fatty acid-modified peptide based on the native GIP sequence. Tirzepatide demonstrated a more significant reduction in glycosylated hemoglobin, superior weight loss, and comparable adverse effects compared to semaglutide in a phase 3 trial. Pancreatitis was observed in four patients in the tirzepatide arm and three patients in the semaglutide
arm during the study duration[55]. Cotadutide is a balanced GLP-1 and glucagon receptor dual agonist. Phase 2 clinical trials for cotadutide were published recently. The efficacy of cotadutide also appears to be better than that of semaglutide, although no head-to-head comparison is available. No case of pancreatitis has been reported in the phase 2a study of cotadutide, although the frequency of nausea and vomiting was increased in the cotadutide arm[56]. We must therefore wait until we have sufficient data on these new drugs. It is premature to make comment on the pancreatic safety of these drugs at present.

CONCLUSION

We have collected extensive data on the safety of incretin-based therapies over the past two decades. It seems that incretin-based therapies do not increase the risk for PC. Instead, new pre-clinical experimental data have shown beneficial effects on cancer cell lines that require further evaluation. The uncertain risks of PC appear to be smaller compared to the beneficial pleiotropic effects of incretin-based therapies. However, with newer incretin-based therapies, we should keep the theoretical possibility of PC in mind and be cautious until we obtain sufficient data.
## ORIGINALITY REPORT

### SIMILARITY INDEX

4%

### PRIMARY SOURCES

<table>
<thead>
<tr>
<th>#</th>
<th>Source</th>
<th>Words</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><a href="http://www.wjgnet.com">www.wjgnet.com</a></td>
<td>27</td>
<td>1%</td>
</tr>
<tr>
<td>2</td>
<td>link.springer.com</td>
<td>20</td>
<td>1%</td>
</tr>
<tr>
<td>3</td>
<td><a href="http://www.semanticscholar.org">www.semanticscholar.org</a></td>
<td>19</td>
<td>1%</td>
</tr>
<tr>
<td>5</td>
<td>worldwidescience.org</td>
<td>13</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>6</td>
<td><a href="http://www.cmaj.ca">www.cmaj.ca</a></td>
<td>13</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>7</td>
<td><a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a></td>
<td>12</td>
<td>&lt;1%</td>
</tr>
</tbody>
</table>

**Exclude Quotes**: ON  
**Exclude Sources**: <12 Words  
**Exclude Bibliography**: ON  
**Exclude Matches**: <12 Words